This single-center, observational study evaluated the LVAD index, defined as device-estimated pump flow divided by body surface area, in adult patients supported with continuous-flow left ventricular assist devices. The study included 34 patients with end-stage heart failure who had either an HVAD or HeartMate 3 device and were followed for six months. The study assessed the relationship between LVAD index and selected routine biochemical markers related to hepatic and renal status, including ALT, AST, LDH, BUN, and creatinine. The study also evaluated whether LVAD index was associated with rehospitalization during follow-up.

This observational cohort study included adult patients with end-stage heart failure supported with continuous-flow left ventricular assist devices. Patients with HVAD and HeartMate 3 devices were followed during routine clinical visits over a six-month period. Device-estimated pump flow, power consumption, and LVAD index were recorded at follow-up visits. LVAD index was calculated as device-estimated pump flow divided by body surface area. Routine laboratory parameters, including ALT, AST, LDH, BUN, and creatinine, were evaluated as selected biochemical markers related to hepatic and renal status and tissue injury. Rehospitalization status during follow-up was also assessed. The study did not assign participants to any intervention and did not include protocol-driven pump speed adjustment.

Inclusion Criteria:

• Age 18 years or older
• Diagnosis of end-stage heart failure
• First-time continuous-flow left ventricular assist device implantation
• Implanted with either an HVAD or HeartMate 3 left ventricular assist device
• Minimum follow-up period of six months

Exclusion Criteria:

• Incomplete data
• Declined participation
• HeartMate II pump implantation
• Significant aortic valve dysfunction, including moderate or severe aortic regurgitation or stenosis

Adult patients with end-stage heart failure who underwent first-time continuous-flow left ventricular assist device implantation and were followed for at least six months. The study population included patients supported with either HVAD or HeartMate 3 devices during routine clinical follow-up.

Individual participant data will not be publicly shared due to patient confidentiality and institutional data protection requirements. De-identified data may be made available from the corresponding author upon reasonable request.